ELAVL1 and non-small cell lung carcinoma: Based on these findings, more experiments and researches need to be done to study whether crizotinib based on ELAVL1, CBLL1, HNRNPC and RBM15B sensitize more of NSCLC cells, thus attenuating drug resistance in LC.